A Comprehensive Covid-19 Response - The Need for Economic Evaluation.
Persad G, Pandya A.
N Engl J Med. 2022 May 04. PMID: 35507511
Dr. Pandya loves teaching introductory health decision science and conducting research built on these methods. His areas of interest are: 1) applied decision science studies evaluating cardiovascular disease policies; 2) connecting cost-effectiveness analysis with broader value-based health policies being implemented or piloted in U.S. health reform; and 3) methodological topics within disease simulation modeling (calibration, validation, value of information). His research has been covered in The New York Times, National Public Radio, NBC Nightly News, and other media outlets.
Before joining HPM, Dr. Pandya served as Assistant Professor of Healthcare Policy and Research with a secondary appointment in the Department of Radiology at Weill Cornell Medical College from 2012-2014. He graduated from the Harvard PhD Program in Health Policy in 2012, and holds an MPH from Yale University in Health Policy and Administration and a BS from Cornell University in Nutritional Sciences. Prior to entering the PhD program, he worked for two years at a health economics/outcomes research consulting firm.
He received the "Outstanding Paper by a Young Investigator Award" from the Society for Medical Decision Making (SMDM) in 2016, and was one of three recipients of the "Teaching Citation Award" from the Harvard T.H. Chan School of Public Health in 2017. He received a "Centre for Health Economics Research Fellowship Award" from the University of York in 2018 (visitation in 2019). He was elected as an SMDM trustee in 2019. Dr. Pandya has received grant funding as principal investigator from the National Institutes of Health (R01NS104143, 2018-2023) and the American Heart Association (14CRP18730014, 2014-2015).
Persad G, Pandya A.
N Engl J Med. 2022 May 04. PMID: 35507511
Sediqzadah S, Portnoy A, Kim JJ, Keshavan M, Pandya A.
Psychiatr Serv. 2022 Feb 23. appips202100161. PMID: 35193372
Bilinski A, MacKay E, Salomon JA, Pandya A.
Value Health. 2022 Feb 23. PMID: 35219599
Zang X, Mah C, Quan AML, Min JE, Armstrong WS, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Kirk GD, Marshall BDL, Mehta SH, Metsch LR, Pandya A, Schackman BR, Shoptaw S, Strathdee SA, Krebs E, Nosyk B.
J Acquir Immune Defic Syndr. 2022 02 01. 89(2):143-150. PMID: 34723929
Pandya A, Yu YJ, Ge Y, Nagel E, Kwong RY, Bakar RA, Grizzard JD, Merkler AE, Ntusi N, Petersen SE, Rashedi N, Schwitter J, Selvanayagam JB, White JA, Carr J, Raman SV, Simonetti OP, Bucciarelli-Ducci C, Sierra-Galan LM, Ferrari VA, Bhatia M, Kelle S.
J Cardiovasc Magn Reson. 2022 01 06. 24(1):1. PMID: 34986851
Boltyenkov AT, Martinez G, Pandya A, Katz JM, Wang JJ, Naidich JJ, Rula E, Sanelli PC.
Front Neurol. 2021. 12:774657. PMID: 34899583
Sarpatwari A, Pandya A, Hyle EP, Persad G.
Ann Intern Med. 2022 02. 175(2):280-282. PMID: 34748375
Krebs E, Enns E, Zang X, Mah CS, Quan AM, Behrends CN, Coljin C, Goedel W, Golden M, Marshall BDL, Metsch LR, Pandya A, Shoptaw S, Sullivan P, Tookes HE, Duarte HA, Min JE, Nosyk B.
AIDS. 2021 11 01. 35(13):2169-2179. PMID: 34148987
Quan AML, Mah C, Krebs E, Zang X, Chen S, Althoff K, Armstrong W, Behrends CN, Dombrowski JC, Enns E, Feaster DJ, Gebo KA, Goedel WC, Golden M, Marshall BDL, Mehta SH, Pandya A, Schackman BR, Strathdee SA, Sullivan P, Tookes H, Nosyk B.
Lancet HIV. 2021 09. 8(9):e581-e590. PMID: 34370977
Kamel H, Parikh NS, Chatterjee A, Kim LK, Saver JL, Schwamm LH, Zachrison KS, Nogueira RG, Adeoye O, Díaz I, Ryan AM, Pandya A, Navi BB.
Stroke. 2021 08. 52(8):2554-2561. PMID: 33980045
Just because a particular health care service is considered not cost effective doesn’t mean it shouldn’t be used, according to a recent article co-authored by Harvard Chan School’s Ankur Pandya.
During the pandemic, Harvard Chan School's Department of Health Policy and Management got creative with virtual programming to keep faculty, staff, and students feeling connected.
Using the coronary artery calcium score to determine when to start statin therapy among African Americans at intermediate risk for atherosclerotic cardiovascular disease is a more cost-effective approach than prescribing the medication to all African American patients at…